A Phase I/IIa Study of AZD8205 given alone or in Combination with Anticancer Drugs, in Participants with Advanced or Metastatic Solid Malignancies

Study identifier:D6900C00001

ClinicalTrials.gov identifier:NCT05123482

EudraCT identifier:2021-000736-66

CTIS identifier:2022-502759-70-01

Recruiting

Official Title

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors (BLUESTAR)

Medical condition

Breast Cancer

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD8205, AZD8205 and AZD2936 (Rilvegostomig)

Sex

All

Estimated Enrollment

340

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 18 Oct 2021
Estimated Primary Completion Date: 30 Jun 2026
Estimated Study Completion Date: 30 Jun 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria